perifosine + dexamethasone

**perifosine + dexamethasone** is a pharmaceutical combination of two drugs used primarily in the context of multiple myeloma, especially relapsed or refractory cases. Perifosine is a synthetic, oral alkylphospholipid that acts as a signal transduction modulator, most notably inhibiting the phosphatidylinositol 3-kinase/Akt pathway and activating the JNK pathway. Dexamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. Perifosine enhances the efficacy of established regimens such as dexamethasone-based therapy, potentially by inhibiting survival and proliferation signals downstream of Akt, which are active in myeloma cells. The combination is not available as a unique brand; it is employed in clinical trials and experimental settings for treating relapsed/refractory multiple myeloma. Perifosine was primarily developed by Keryx Biopharmaceuticals. Dexamethasone is a well-established generic drug manufactured by many pharmaceutical companies globally. Mechanistically, perifosine acts as an Akt pathway inhibitor, leading to reduced cell survival, while dexamethasone acts on the glucocorticoid receptor as an agonist, resulting in immunosuppression and apoptosis induction in lymphoid tissue. Primary indication is for the treatment of multiple myeloma, especially in relapsed/refractory disease when other lines of therapy have failed[2][5].